Table 3.
Summary of efficacy endpoints by administration period
| Biochemical control | n | Self/partner administration | HCP administration | ||
|---|---|---|---|---|---|
|
|
|
||||
| Before | After | Before | After | ||
| Mean (SD) Cg A, nmol/L |
22 | 37.5 (58.4) | 47.9 (74.9) | 42.1 (70.7) | 37.4 (58.0) |
| Mean (SD) 5-HIAA, μmol/day |
12 | 220.2 (238.3) | 219.2 (227.6) | 217.1 (244.3) | 219.6 (218.5) |
|
| |||||
| Patient experiences | Training | Self/partner administration | HCP administration | ||
|
| |||||
| Interference of at least one injection with: n (%) | |||||
| Activities of daily living | 6 (24%) | 2 (8%) | 6 (24%) | ||
| Psychological well being | 4 (16%) | 2 (8%) | 1 (4%) | ||
Notes: Data are from the intention-to-treat population (n = 25) except for urinary 5-HIAA levels, which were measured as judged necessary by the investigator. Data are presented only for patients with values for all three visits in an administration block. Reference values for Cg A and urinary 5-HIAA were <4.0 nmol/L and >50 μmol/day, respectively.
Abbreviations: Cg A, chromogranin A; 5-HIAA, 5-hydroxyindoleacetic acid; HCP, health care professional; SD, standard deviation.